PTPA and neoplasm: Bortezomib, a potent inhibitor of the 26S proteasome with broad anti-tumor effects, reportedly decreases the expression of CIP2A, another PP2A inhibitory protein, to exert anti-tumor effects on human triple negative breast cancer cells28.